Mn Services Vermogensbeheer B.V. Boosts Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Mn Services Vermogensbeheer B.V. grew its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 41,213 shares of the biopharmaceutical company’s stock after buying an additional 713 shares during the quarter. Mn Services Vermogensbeheer B.V.’s holdings in Regeneron Pharmaceuticals were worth $31,811,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of REGN. Private Advisory Group LLC bought a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter valued at about $216,000. ORG Partners LLC grew its position in Regeneron Pharmaceuticals by 81.6% during the 4th quarter. ORG Partners LLC now owns 69 shares of the biopharmaceutical company’s stock worth $53,000 after acquiring an additional 31 shares during the last quarter. Northwest Wealth Management LLC bought a new position in Regeneron Pharmaceuticals during the 4th quarter worth approximately $366,000. Woodstock Corp increased its stake in Regeneron Pharmaceuticals by 12.3% in the 4th quarter. Woodstock Corp now owns 18,646 shares of the biopharmaceutical company’s stock worth $14,392,000 after purchasing an additional 2,036 shares during the period. Finally, Chesley Taft & Associates LLC increased its stake in Regeneron Pharmaceuticals by 184.4% in the 4th quarter. Chesley Taft & Associates LLC now owns 1,237 shares of the biopharmaceutical company’s stock worth $955,000 after purchasing an additional 802 shares during the period. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Up 1.6%

REGN stock opened at $749.29 on Tuesday. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $821.11. The company has a market capitalization of $79.21 billion, a price-to-earnings ratio of 18.03, a price-to-earnings-growth ratio of 1.98 and a beta of 0.40. The business’s 50 day moving average price is $765.00 and its two-hundred day moving average price is $709.34. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.39 and a current ratio of 4.13.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 EPS for the quarter, beating the consensus estimate of $10.74 by $0.70. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The business had revenue of $3.88 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same quarter last year, the firm posted $12.07 earnings per share. The company’s revenue for the quarter was up 2.5% on a year-over-year basis. As a group, analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 5th. Shareholders of record on Friday, February 20th were given a $0.94 dividend. The ex-dividend date was Friday, February 20th. This is a boost from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. This represents a $3.76 annualized dividend and a yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is 9.05%.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on REGN. Morgan Stanley increased their price objective on Regeneron Pharmaceuticals from $768.00 to $769.00 and gave the company an “equal weight” rating in a research note on Monday, February 2nd. Oppenheimer restated an “outperform” rating and issued a $865.00 price objective (up from $750.00) on shares of Regeneron Pharmaceuticals in a research report on Monday, February 2nd. Cantor Fitzgerald upped their price objective on shares of Regeneron Pharmaceuticals from $740.00 to $800.00 and gave the company an “overweight” rating in a research note on Monday, February 2nd. BMO Capital Markets increased their price objective on Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the stock an “outperform” rating in a report on Thursday, December 4th. Finally, Royal Bank Of Canada lifted their price objective on Regeneron Pharmaceuticals from $745.00 to $765.00 and gave the stock a “sector perform” rating in a research report on Monday, March 2nd. Two research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $802.27.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, SVP Jason Pitofsky sold 2,036 shares of the stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $778.52, for a total transaction of $1,585,066.72. Following the completion of the transaction, the senior vice president owned 4,272 shares of the company’s stock, valued at $3,325,837.44. This represents a 32.28% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Arthur F. Ryan sold 100 shares of the stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $778.53, for a total value of $77,853.00. Following the transaction, the director owned 17,803 shares of the company’s stock, valued at $13,860,169.59. This represents a 0.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 5,274 shares of company stock valued at $4,142,738 in the last 90 days. 7.02% of the stock is owned by company insiders.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.